MA28104A1 - Sel antagonistes de ccr-2 - Google Patents

Sel antagonistes de ccr-2

Info

Publication number
MA28104A1
MA28104A1 MA28957A MA28957A MA28104A1 MA 28104 A1 MA28104 A1 MA 28104A1 MA 28957 A MA28957 A MA 28957A MA 28957 A MA28957 A MA 28957A MA 28104 A1 MA28104 A1 MA 28104A1
Authority
MA
Morocco
Prior art keywords
salt
ccr
antagonists
succinate salt
methoxytetrahydro
Prior art date
Application number
MA28957A
Other languages
English (en)
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28104A1 publication Critical patent/MA28104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention fournit une synthèse efficace pour la préparation de ((1R,3S)-3-isopropyl-3-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé et son sel succinate. La présente invention fournit en plus une synthèse efficace pour la préparation des intermédiaires (3R)-3-méthoxytétrahydro-4H-pyran-4-one; acide (1S,4S)-4-(2,5-diméthyl- 1H-pyrrol- 1-yl)-1-isopropylcyclopent-2-ene-1-carboxylique; et 3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,6-naphtydirine; et pour la préparation du précurseur (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopent-2-en-1-yl)-3-méthoxytétrahydro-2H-pyran-4-amine. L'invention concerne en outre les propriétés supérieures du sel succinate de ((1R,3S)-3-isopropyl-3-{[3-(trifiuorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl]carbonyl}cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé.
MA28957A 2003-10-27 2006-04-24 Sel antagonistes de ccr-2 MA28104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27

Publications (1)

Publication Number Publication Date
MA28104A1 true MA28104A1 (fr) 2006-08-01

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28957A MA28104A1 (fr) 2003-10-27 2006-04-24 Sel antagonistes de ccr-2

Country Status (21)

Country Link
US (1) US7473696B2 (fr)
EP (1) EP1682135B1 (fr)
JP (1) JP4542550B2 (fr)
KR (1) KR20060101476A (fr)
CN (1) CN1870998B (fr)
AT (1) ATE517622T1 (fr)
AU (1) AU2004287416C1 (fr)
BR (1) BRPI0415836A (fr)
CA (1) CA2543201C (fr)
CO (1) CO5690606A2 (fr)
EC (1) ECSP066524A (fr)
IL (1) IL175009A0 (fr)
IS (1) IS8400A (fr)
MA (1) MA28104A1 (fr)
MX (1) MXPA06004647A (fr)
NO (1) NO20062377L (fr)
NZ (1) NZ546447A (fr)
RU (1) RU2317295C1 (fr)
UA (1) UA81365C2 (fr)
WO (1) WO2005044264A1 (fr)
ZA (1) ZA200602752B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
EP1565436B1 (fr) 2002-11-27 2012-04-25 Incyte Corporation Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
CN1826334A (zh) * 2003-03-18 2006-08-30 麦克公司 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
KR20080052683A (ko) 2003-12-18 2008-06-11 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
BRPI0510665A (pt) 2004-05-11 2007-12-04 Incyte Corp 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
MXPA06014672A (es) 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas.
WO2006004741A2 (fr) 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides utilises en tant que modulateurs des recepteurs des chimiokines
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (fr) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés d'amino cyclopentane substitués par cyclohexane en tant qu'antagonistes utiles de ccr2
WO2013149376A1 (fr) 2012-04-02 2013-10-10 Abbott Laboratories Antagonistes de récepteurs de chimiokines
HK1216233A1 (zh) 2013-02-28 2016-10-28 参天制药株式会社 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼後段疾病的预防或治疗剂
DK3297438T3 (da) 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
CA3293051A1 (en) 2017-09-25 2026-03-02 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
WO2000076512A1 (fr) * 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine
EP1318811B1 (fr) 2000-08-17 2006-08-30 Merck & Co., Inc. Modulateurs cyclopentyles de l'activite du recepteur de la chimiokine
IL155371A0 (en) * 2000-11-28 2003-11-23 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
EP1461040B1 (fr) * 2001-11-29 2006-03-15 Pfizer Products Inc. Sels succiniques de 5,8,14-triazatetracyclo 10.3.1.02,11.0 4,9 -hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques associees
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
DE60322877D1 (de) * 2002-04-29 2008-09-25 Merck Sharp & Dohme Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
EP1501507B1 (fr) * 2002-04-29 2008-05-28 Merck & Co., Inc. Modulateurs tetrahydropyranyl cyclopentyl tetrahydropyridopyridine de l'activite des recepteurs de chimiokine
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
AU2004287416C1 (en) 2010-09-09
EP1682135A1 (fr) 2006-07-26
RU2317295C1 (ru) 2008-02-20
EP1682135B1 (fr) 2011-07-27
KR20060101476A (ko) 2006-09-25
ATE517622T1 (de) 2011-08-15
BRPI0415836A (pt) 2007-01-02
UA81365C2 (en) 2007-12-25
IS8400A (is) 2006-04-06
JP2007509940A (ja) 2007-04-19
AU2004287416B2 (en) 2009-11-19
ZA200602752B (en) 2007-08-29
EP1682135A4 (fr) 2009-11-25
JP4542550B2 (ja) 2010-09-15
CN1870998B (zh) 2010-10-20
NO20062377L (no) 2006-05-24
CA2543201C (fr) 2010-12-21
CO5690606A2 (es) 2006-10-31
MXPA06004647A (es) 2006-06-27
WO2005044264A1 (fr) 2005-05-19
NZ546447A (en) 2009-02-28
IL175009A0 (en) 2006-08-20
US7473696B2 (en) 2009-01-06
ECSP066524A (es) 2006-10-10
US20070135474A1 (en) 2007-06-14
AU2004287416A1 (en) 2005-05-19
CA2543201A1 (fr) 2005-05-19
CN1870998A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
MA28104A1 (fr) Sel antagonistes de ccr-2
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
IL166235A (en) H-1-pyrolidine-4,2-deion spirocyclic annihilated conjugates in cisal alkoxies for use as pesticides, their preparation and intermediates
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
DE60312701D1 (de) Darstellung von 1h-imidazoä4,5-cüchinolin-4-aminen über neue 1h-imidazoä4,5-cüchinolin-4-cyano- und 1h-imidazoä4,5-cüchinolin-4-carboxamid intermediate
WO2005037198A3 (fr) Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
WO2005040169A3 (fr) Composes heterocycliques fusionnes
PL378812A1 (pl) Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
PT1622569E (pt) Derivados de aza espiro alcanos como inibidores de metaloproteases
EP1656138A4 (fr) Derives de cycloalkyamine substitues en tant que modulateurs de l'activite du recepteur de la chimiokine
GEP20074210B (en) Tropane derivatives as ccr5 modulators
MX2011005935A (es) Compuestos organicos.
RU2009140095A (ru) Гетероарильные производные
WO2005049561A3 (fr) Procedes de preparation d'un nouveau derive de bleu de methylene
WO2004106340A3 (fr) Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et pyrrolo[2,3-d]pyrimidine et utilisations associees
IL175958A0 (en) Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
AR045875A1 (es) Procedimiento para la preparacion del antagonista ccr-2
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
DE60008400D1 (de) Triazolopyrimidinderivate
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
EP1786815A4 (fr) Composes spiro et procedes pour la modulation de l'activite de recepteur de chimiokine
EA200501829A1 (ru) Способ получения непептидных замещённых спиробензоазепиновых производных
DE602004009962D1 (de) Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen
UA98797C2 (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity